A practical safety checklist for psilocybin assisted therapy starts with who should not proceed, then covers medication and substance interactions, mental health history flags, session-day monitoring and a clear follow-up plan. Current clinical investigation guidance and published trial safety reporting point to the same priorities, careful screening, supervised dosing with monitoring, documented plans for adverse reactions and structured follow-up.
Who tends to be screened out and why
Screening is designed to reduce predictable risk. You will see similar exclusion patterns across many published protocols because the acute effects can be intense and the physiological response can include short-term increases in blood pressure and heart rate.
You tend to be screened out when your baseline risk is elevated in one of three areas.
Medical risk
Many protocols exclude uncontrolled hypertension, significant cardiovascular disease and other conditions where transient blood pressure or heart rate increases could be unsafe. Some trials also set clear resting blood pressure cutoffs at screening and repeat measurements to confirm baseline values. (UCLA Health)
Acute psychiatric risk
Protocols commonly exclude current suicidality that requires urgent treatment, recent psychiatric hospitalization and unstable symptoms that could make dosing day harder to manage. Even in well-supported settings, an acute shift into panic, agitation or despair can happen, so screening aims to reduce that risk. (JAMA Network)
Risk for psychosis or mania
Many studies exclude a personal history of psychotic disorders and bipolar I disorder. Many also exclude people with certain family history patterns tied to psychosis or bipolar disorder, since these are associated with higher risk for adverse psychiatric outcomes in psychedelic exposure. (PMC)
You may also be screened out for practical reasons that still connect to safety.
- You cannot identify a safe ride home and an adult support person after dosing day
- You cannot commit to follow-up visits and check-ins
- You are currently using substances in a way that raises withdrawal risk or destabilizes symptoms
- You have recently used psychedelics, which can complicate baseline assessment in some protocols (CenterWatch)
Screening out does not mean a protocol thinks you are a bad candidate forever. It usually means the specific study cannot responsibly take on your risk profile. Clinical investigations guidance emphasizes ethical conduct, participant safety and interpretable results, which is why exclusion criteria often feel strict. (U.S. Food and Drug Administration)
Medication and substance interaction topics to cover
Medication review is not a formality. It is one of the highest-yield safety steps because it can reveal interaction risks, taper risks and symptom stability risks. A 2023 systematic review of drug-drug interactions involving classic psychedelics highlights that interaction evidence is still limited in humans for many combinations, so clinicians lean on pharmacology, case reports and protocol conservatism.
Your medication discussion usually needs four layers.
Layer one is serotonergic medications
Many psychiatric medications affect serotonin signaling. Psilocybin also acts through serotonin receptors. That can raise theoretical risks in some combinations and can change subjective effects in others. Evidence across studies is mixed and depends on the specific medication class and dosing patterns, but your prescriber should be part of the conversation, especially if any taper is considered. (PMC)
Layer two is medications tied to seizure risk
Some drug combinations may raise seizure risk, and case-based concerns have been raised around lithium with classic psychedelics. You should treat this topic as high priority in screening discussions because seizures and severe agitation are events protocols work hard to prevent. (PMC)
Layer three is cardiovascular medications and stimulants
Even if you are healthy, psilocybin can raise blood pressure and heart rate in the acute window. If you are on stimulants, thyroid medications or other agents that affect autonomic tone, the protocol team needs to know. You also need to discuss over-the-counter decongestants, nicotine products and energy supplements, since these can raise blood pressure for some people. (ScienceDirect)
Layer four is substances and withdrawal risk
Alcohol, benzodiazepines and other sedatives raise specific issues. Some raise withdrawal risk if you stop abruptly. Some can interfere with the protocol. Some can be used in emergency management settings, which can complicate safety planning if you have tolerance or dependence. Screening often looks at substance use patterns because acute dosing day support needs to anticipate agitation, panic, insomnia and rebound symptoms. (PMC)
When you prepare for a screening interview, bring a complete list.
- Prescription medications with doses and timing
- Over-the-counter medications you use weekly or more
- Supplements, sleep aids and weight loss products
- Recent changes in meds, missed doses and side effects
- Caffeine, nicotine, alcohol and other substance use patterns
You should also talk about taper safety in direct terms. If a study requires a washout, your prescriber should help evaluate relapse risk, withdrawal risk and timing. Some emerging research suggests concomitant antidepressant use with classic psychedelics can be tolerable in certain contexts, but decisions are still protocol-specific and diagnosis-specific. (SAGE Journals)
Mental health history factors clinicians flag
Mental health screening is not only about diagnosis labels. It is about stability, risk patterns and how you respond under stress.
The most consistently flagged history areas include these.
Personal history of psychosis or mania
Most clinical trials exclude psychotic disorders and bipolar I disorder. Many also exclude bipolar II depending on protocol and monitoring resources. This is tied to the risk of precipitating mania or psychosis-like states during or after dosing. (clinicaltrials.gov)
Family history patterns
Many protocols screen for first-degree family history of schizophrenia-spectrum disorders, psychotic disorders and bipolar I disorder. A 2024 review focused on family history and bipolar risk discusses why genetic loading for psychosis and mood disorders is treated as relevant when assessing psychedelic exposure risk. (PMC)
Current suicidality and recent crisis
Trials commonly exclude active suicidality above defined thresholds and recent instability that would require acute care. Serious adverse events are uncommon in published psilocybin trials, but some safety reporting reviews note rare events tied to suicidality in depressive disorder populations, which is why screening remains strict. (ScienceDirect)
Severe dissociation, trauma instability and panic patterns
A psilocybin session can involve intense autobiographical content, fear and perceptual changes for hours. Clinicians look for patterns that could raise risk of severe panic, unsafe behavior or prolonged destabilization. Preparation can help, yet screening is still the first filter. (U.S. Food and Drug Administration)
Personality disorder patterns that raise safety concerns
Some protocols exclude certain cluster B diagnoses or severe traits linked to impulsivity and unstable behavior, mainly to reduce risk in an altered state and to keep follow-up stable and safe. (UCLA Health)
If you want your screening conversation to be useful, describe your history in practical terms.
- Episodes of mania or hypomania and what they looked like for you
- Any psychotic symptoms, even brief or substance-associated
- Hospitalizations, emergency visits and crisis calls in the last year
- Self-harm history and current suicidal thoughts, including passive thoughts
- Sleep patterns, since sleep disruption can increase risk for mood episodes
- Trauma triggers and dissociation patterns
Clinical investigation guidance also emphasizes that psychedelic drug development programs face unique challenges because altered consciousness can last several hours, and some programs include psychological interventions. That is why mental health screening goes beyond diagnosis and looks at how the full day will be managed safely. (U.S. Food and Drug Administration)
Session safety plan basics
A safety plan for the session day is a written plan, not an assumption. You want clarity on setting, staffing, monitoring and what happens if your experience becomes overwhelming.
Setting and monitoring
A typical monitored session in clinical investigations has these features.
Private room and controlled environment
The space is quiet, predictable and designed to minimize interruptions. The goal is to reduce external stressors that can amplify fear and agitation.
Trained staff present for the full acute window
Many protocols use two monitors or clinicians, especially at higher doses, with clear roles for emotional support and for medical monitoring. (U.S. Food and Drug Administration)
Vital sign monitoring
Short-term increases in blood pressure and heart rate are commonly reported. That is why protocols check baseline vitals and repeat checks during the session. The feasibility trial registry report for a psilocybin study notes non-clinically significant elevations in blood pressure and heart rate as common, which fits broader safety reporting. (clinicaltrials.gov)
Basic medical readiness
You should ask what equipment is on hand, what the threshold is for calling emergency services and who makes that call. You should also ask how nausea, vomiting, headache and anxiety are managed during and after the session, since these are among the most commonly reported acute adverse effects in therapeutic dosing. (JAMA Network)
Discharge criteria and transport
A safe discharge plan confirms you are oriented, steady on your feet and able to leave with a prearranged ride. Many protocols require you to avoid driving until the next day.
If you want a practical benchmark for common acute effects, a 2024 analysis of therapeutic doses reported headache, nausea, anxiety, dizziness and elevated blood pressure as common, usually resolving within a short window. That list is useful because it gives you concrete topics to bring into your safety plan discussion. (JAMA Network)
Adverse reaction plan
Your adverse reaction plan should cover psychological distress and medical issues.
Psychological distress plan
Ask what staff do when you panic, become agitated or feel trapped. Ask how they coach you through fear, and what techniques they use for grounding. Ask if they allow you to change posture, move, use the restroom and how staff handle requests to stop.
Medical escalation plan
Ask what vitals thresholds trigger extra monitoring, medication and emergency evaluation. Ask how nausea and vomiting are handled. Ask how severe headache is handled. Ask how staff document adverse events and how follow-up calls happen in the first 24 to 72 hours.
Medication use during emergencies
Some protocols have standing orders for specific medications used to manage severe agitation, severe hypertension or other events. You should ask what those are and how they interact with your current prescriptions.
A 2025 review focused on adverse event reporting and management across psilocybin studies found that blood pressure increases were commonly observed, and serious adverse events were infrequent, with rare events including suicidality in depressive disorder settings. That is the kind of safety reporting that should shape your adverse reaction plan discussion. (ScienceDirect)
Follow-up and integration planning
Follow-up planning is part of safety, not a bonus. Many risks show up after the acute effects have passed.
Your follow-up plan should cover time, support and symptom tracking.
Time and intensity
Ask how many integration visits are scheduled, and how soon the first follow-up happens. A plan that includes check-ins in the first few days is common in trials because it can catch insomnia, anxiety spikes and mood shifts early. (U.S. Food and Drug Administration)
Support at home
Plan a quiet day after dosing. Identify a trusted adult who can be available that evening. If you live alone, talk about how you will reach support if you feel distressed late at night.
Behavioral guardrails
Write down what you will not do in the first week, like major life decisions, ending relationships, quitting a job or stopping medications without supervision. The session can feel clarifying, but you still need time for integration and sleep normalization.
Symptom tracking
Track sleep, appetite, anxiety, irritability and suicidal thoughts daily for at least a week. Many studies use structured symptom scales at follow-ups, but your own daily notes can help you communicate changes early.
Coordination with your clinician
If you have a prescriber or therapist, decide ahead of time what information you will share and when. If medication changes are involved, agree on a plan for setbacks.
Safety reporting reviews stress that adverse events are usually transient, yet rare serious events have been documented, which supports close follow-up and a clear escalation path. (PMC)
A one-page checklist based on clinical investigation norms
Use this checklist as a screening and planning tool. It is written to match how clinical investigations are designed, with a focus on predictable risk points, documentation and follow-up. (U.S. Food and Drug Administration)
Screening and eligibility
- Diagnosis confirmed with a structured assessment
- Baseline symptom severity documented
- Medical history reviewed with focus on cardiovascular risk and seizure history
- Physical exam completed as needed
- Resting blood pressure and heart rate measured more than once if elevated
- Labs or ECG reviewed if your history suggests risk
- Personal history reviewed for psychosis, mania, severe dissociation and recent crisis
- Family history reviewed for schizophrenia-spectrum disorders, psychotic disorders and bipolar I disorder
- Current suicidality assessed with a clear threshold for exclusion or stabilization first (UCLA Health)
Medication and substance review
- Full medication list reviewed with doses and timing
- Over-the-counter meds and supplements included
- Serotonergic meds discussed with protocol rules and prescriber input
- Lithium and seizure risk topics discussed if relevant
- Stimulants, decongestants, nicotine and high caffeine use reviewed
- Alcohol and sedative use assessed for withdrawal risk
- A plan documented for any taper or washout, with relapse safeguards (PMC)
Preparation plan
- Preparation visits scheduled with clear goals
- Expectations discussed for perceptual changes lasting hours
- Coping skills practiced for fear, panic and loss of control feelings
- A plan documented for personal triggers and grounding techniques
- A written plan for what you want to focus on during the session (U.S. Food and Drug Administration)
Session day plan
- Private room and minimized interruptions confirmed
- Staff roles defined for support and monitoring
- Vital sign monitoring schedule documented
- Nausea, headache and anxiety management plan documented
- Escalation thresholds documented for hypertension, agitation and confusion
- Transport home arranged in advance
- Discharge criteria documented, including no driving until the next day (clinicaltrials.gov)
Adverse reaction plan
- Steps for panic and agitation documented
- Steps for severe hypertension documented
- Steps for suicidality in the days after documented
- Who to call after hours and response time clarified
- When emergency services are used clarified (ScienceDirect)
Follow-up and integration plan
- First follow-up scheduled within a defined window
- Integration visits scheduled and attendance expectations set
- Daily self-tracking plan for sleep, anxiety and mood for at least one week
- Coordination plan with your clinician for medication management and relapse signals
- A plan to avoid major life decisions in the first week written down
If you want to see how we think about safety, screening and follow-up in the context of psilocybin science and therapeutic integration, we are Rose Hill Life Sciences, a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and we are based in Massachusetts.
